Keymed Biosciences Reports 67% YoY Revenue Increase in 2025, Approvals for Kangyueda® and Milestone Payments for CMG901 and CM336.

Keymed Biosciences reported a 67% YoY increase in total revenue to RMB 720m in 2025, driven by RMB 310m from sales of Kangyueda and RMB 410m from collaboration income. The company's R&D expenses reached RMB 720m, and cash reserves stood at RMB 1.96bn as of December 31, 2025. All launched indications for Kangyueda have been included in China's National Reimbursement Drug List, enhancing affordability and accessibility for patients.